SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6609-6618

  Roth, Patrick ^a,b   Kissel, Maria ^c   Herrmann, Caroline ^b   Eisele, Günter ^a,b   Leban, Johann ^c   Weller, Michael ^a,b   Schmidt, Friederike ^b,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c 4SC AG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; INITIATOR CASPASE; PROTEASOME INHIBITOR; SC 68896; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL DENSITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; ENZYME ACTIVITY; GLIOMA CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LNT 229 GLIOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; SENSITIZATION; SURVIVAL; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FAS LIGAND PROTEIN; GLIOMA; HUMANS; MICE; MICE, NUDE; PROTEASOME ENDOPEPTIDASE COMPLEX; SEMICARBAZONES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350704804     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0548     Document Type: Article

References (26)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996 (Pubitemid 40349501)
2. Thompson SJ, Loftus LT, Ashley MD, Meller R. Ubiquitin-proteasome system as a modulator of cell fate. Curr Opin Pharmacol 2008;8:90-95 (Pubitemid 351168692)
3. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005;23:4776-4789 (Pubitemid 46224082)
4. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498 (Pubitemid 41007864)
5. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675 (Pubitemid 46224166)
6. Labussiere M, Pinel S, Delfortrie S, Plenat F , Chastagner P. Proteasome inhibition by bortezomib does not translate into efficacy on twomalignant glioma xenografts. Oncol Rep 2008;20:1283-1287
7. Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett 1998;427:124-128
8. Leban J, Blisse M, Krauss B, Rath S, Baumgartner R, Seifert MH. Proteasome inhibition by peptidesemicarbazones. Bioorg Med Chem 2008;16:4579-4588
9. Rensing-Ehl A, Frei K, Flury R, et al. Local Fas/ APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995;25:2253-2258
10. Bähr O, Rieger J, Duffner F, Meyermann R, Weller M, Wick W. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathol 2003;13:482-494 (Pubitemid 37420693)
11. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003;22:8233-8245 (Pubitemid 37485516)
12. Wagenknecht B, Glaser T, Naumann U, et al. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ 1999;6:370-376 (Pubitemid 29186881)
13. Webb JL. Enzyme and metabolic inhibitors. 1st ed New York: Academic Press; 1963.
14. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-360
15. Wagenknecht B, Hermisson M, Eitel K, Weller M. Proteasome inhibitors induce p53/ p21-independent apoptosis in human glioma cells. Cell Physiol Biochem 1999;9:117-125 (Pubitemid 29439096)
16. Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007;67:4981-4988 (Pubitemid 46910207)
17. Wagenknecht B, Hermisson M, Groscurth P, Liston P, Krammer PH, Weller M. Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem 2000;75:2288-2297 (Pubitemid 30832731)
18. Koschny R, Holland H, Sykora J, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 2007;13:3403-3412 (Pubitemid 46944929)
19. Röhn TA, Wagenknecht B, Roth W, et al. CCNU-dependent potentiation of TRAIL/Apo2Linduced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 2001;20:4128-4137 (Pubitemid 32762187)
20. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med2002;8:808-815
21. La Ferla-Bruhl K, Westhoff MA, Karl S, et al. NF-êB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene 2007;26:571-582 (Pubitemid 46160970)
22. Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005;24:344-354 (Pubitemid 40188583)
23. Guan B, Yue P, Clayman GL, Sun SY. Evidence that the death receptor DR4 is a DNA damageinducible, p53-regulated gene. J Cell Physiol 2001;188:98-105. (Pubitemid 32476500)
24. Wu GS, Burns TF, McDonald ER III, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-143
25. Laurent N, de Bouard S, Guillamo JS, et al. Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 2004;3:129-136 (Pubitemid 39193687)
26. Zavrski I, Naujokat C, Niemoller K, et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003;129:383-391 (Pubitemid 36995137)